News | 3-D Printing | March 13, 2017

Enrollment Started for 3-D Printing Trial in Congenital Heart Cases

Stratasys opens enrollment for 3DHEART multi-center study to evaluate effects of 3-D-printed pediatric heart models on pre-operative planning

Stratasys, 3DHEART trial, open enrollment, 3-D printed pediatric heart models

March 13, 2017 — Stratasys Ltd. announced last week enrollment is now open for 3DHEART, an investigator-initiated trial. 3DHEART, which stands for 3D Hearts Enabling A Randomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3-D-printed models in pre-operative planning for pediatric heart surgery. Stratasys is providing in-kind support with printing of the models to be used in the trial.

The study is being led by physicians from New York-Presbyterian/Morgan Stanley Children's Hospital, Children’s Hospital of Philadelphia, Children’s National Medical Center and Phoenix Children’s Hospital, with up to 20 additional sites in the U.S. The study will focus on pediatric congenital heart patients requiring complex two-ventricle repair. The primary endpoint being studied is cardiopulmonary bypass time, with secondary endpoints including the prevalence of surgical complications (morbidity), mortality and physician assessment of utility. The study is being managed by OpHeart, a 501(c)3 nonprofit organization whose mission is to improve the odds and outcomes for children born with life-threatening heart defects.

“This study is incredibly important because it will finally quantify what we know from firsthand experience: 3-D-printed, patient-specific models improve surgery, improve outcomes and result in lower treatment costs,” said Yoav Dori, M.D., pediatric cardiologist, Children’s Hospital of Philadelphia. “If we can empirically demonstrate this, it will be a game-changer for treating not only children with congenital heart defects, but patients across the board.”

The study will enroll 400 pediatric patients in total. Stratasys Direct Manufacturing is 3-D printing heart models for 200 patients on Stratasys Connex multi-material, full-color 3-D printers. These models are based on the patients’ magnetic resonance imaging (MRI) or computed tomography (CT) scans, and enable the surgeon to evaluate and “practice” on an accurate replica of the patient’s heart prior to actual surgery. The results of these 200 patients are being compared to the results of 200 patients who are being treated without the aid of 3-D-printed heart models.

For more information: www.stratasys.com

Related Content

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies| March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low do
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals| March 22, 2017
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of...
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers| March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies
Feature | ACC| March 22, 2017
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presente
Echopixel, True 3D Viewer, interactive virtual reality, pediatric surgery, increased clinical adoption
News | Advanced Visualization| March 21, 2017
March 21, 2017 — EchoPixel recently announced progress in the clinical adoption of its True 3D...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
iFR, iFR vs. FFR, ACC late breaking trial, iFR-SWEDEHEART, DEFINE-FLAIR, Justin E. Davies,

Matthias Götberg, principal investigator for the iFR-SWEDEHEART study, and Justin E. Davies, lead investigator for the DEFINE-FLAIR trial, share key points of their study with DAIC editor Dave Fornell at ACC.17. The trials showed iFR is equal in outcomes to FFR in assessing coronary lesions. 

Feature | FFR Catheters| March 20, 2017
March 20, 2017 — For patients experiencing angina (chest pain) or a heart attack, instantaneous wave-free ratio (iFR)
Michael Reardon, SURTAVI, TAVR equals surgery in intermediate risk patients

SURTAVI Trial principal investigator Michael Reardon presents the data as a lake-breaker at ACC 2017. 

News | Heart Valve Technology| March 17, 2017 | Dave Fornell
March 17, 2017 - Transcatheter aortic valve replacement (TAVR) was found to be noninferior to surgical aortic valve r
Overlay Init